Seattle Genetics Achieves Milestones as Genentech Advances Two Antibody …DailyFinanceThe phase II randomized, open-label study is designed to evaluate the safety and efficacy of ADCs anti-CD22 (DCDT2980S, RG7593) and DCDS4501A (RG7596) each in combin…
VIDEO: Clinical Exercise Testing in ME/CFS Research & TreatmentProHealthOther presentations on YouTube (not in English) were: • “B-lymphocyte depletion as a therapeutic intervention for chronic fatigue syndrome/ME” by the rituximab trial rese…
Pick Biotech Winners Like A Pro: John McCamantSeeking AlphaThat would be a huge leg up for the stock, at another 100 points. TLSR: And the B-cell lymphomas are a great trail to follow. JM: Exactly. When Rituxin [rituximab] was in development, it was a …
Roche Faces New Foe as Boehringer Plans a Rituxan CopyBloombergRituxan, also know by its generic name rituximab, had 6 billion Swiss francs ($6.45 billion) in sales last year. Roche's patents on the medicine expire in 2018 in the U.S. and earlier i…
Swiss Stocks Extend 19-Month High After US Jobs ReportBloombergLonza Group AG (LONN) slipped 2.6 percent to 49.29 francs. Lonza and Teva Pharmaceutical Industries Ltd. are still evaluating the path forward for a phase III trial of its rituximab generic…
Lonza Drops on Roche Drug Copy Testing Concerns: Zurich MoverBusinessweekTeva and Lonza have not started phase III trials for rituximab, a generic copy of Rituxan, Dirk Oehlers, a spokesman for Lonza, said by telephone. The company is evaluating how to…
Lonza Drops on Roche Drug Copy Testing Concerns: Zurich MoverBloombergTeva and Lonza have not started phase III trials for rituximab, a generic copy of Rituxan, Dirk Oehlers, a spokesman for Lonza, said by telephone. The company is evaluating how to mo…
Lonza et Teva examinent la voie à suivre pour l'homologation du RituximabRomandie.comBâle (awp) – Lonza veut clarifier la situation actuelle du développement de son produit "Rituximab" en raison de rumeurs et d'articles de presse p…
LONZA GROUP AG : Clarification on Biosimilar Activities4-tradersBasel, 05 October 2012 – Following several reports and rumors in the past few days in relation to the Biosimilar activities of the joint venture of Lonza and Teva, Lonza wants to clarify t…
Lonza und Teva prüfen weiter Wege zur Zulassung für das Biosimilar Rituximabfinanzen.chBasel (awp) – Lonza sieht sich aufgrund von Presseberichten und Gerüchten dazu veranlasst, die aktuelle Situation um die Entwicklung des Medikaments Rituximab kla…